Merck - 63 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1962 adjusted for splits and dividends. The latest closing stock price for Merck as of June 20, 2025 is 79.06.
  • The all-time high Merck stock closing price was 128.62 on June 24, 2024.
  • The Merck 52-week high stock price is 134.63, which is 70.3% above the current share price.
  • The Merck 52-week low stock price is 73.31, which is 7.3% below the current share price.
  • The average Merck stock price for the last 52 weeks is 100.02.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2025 85.4959 97.3459 99.1619 72.7417 79.0600 -19.04%
2024 114.2857 108.2040 128.6170 93.7878 97.6502 -6.26%
2023 101.7879 103.3070 110.8010 95.0364 104.1710 1.01%
2022 82.1089 69.2267 104.2170 66.2008 103.1300 49.42%
2021 67.0660 67.1327 80.7712 59.8440 69.0195 1.75%
2020 65.8850 73.9716 73.9716 53.8059 67.8292 -7.20%
2019 65.0953 59.1399 73.7306 57.0510 73.0956 22.27%
2018 49.4130 42.6771 61.6417 40.7642 59.7814 39.95%
2017 46.4128 44.3024 49.7991 40.7214 42.7151 -1.49%
2016 41.6331 37.4437 47.4807 34.6682 43.3597 15.05%
2015 39.6238 39.4870 43.5192 34.2510 37.6863 -3.89%
2014 38.8450 33.1578 42.4047 33.1578 39.2108 16.93%
2013 30.4690 26.6984 33.5330 26.3819 33.5330 26.83%
2012 26.0795 23.7420 30.6794 23.1282 26.4400 13.14%
2011 20.6146 21.3308 23.4940 18.0431 23.3700 9.56%
2010 20.8221 20.9938 23.2742 18.2388 21.3308 2.91%
2009 16.3686 16.6821 21.5554 11.4847 20.7272 26.70%
2008 19.4042 29.5438 31.1813 12.4978 16.3592 -45.33%
2007 25.7011 21.9965 31.2946 21.4569 29.9248 37.35%
2006 18.7667 15.7211 22.8975 15.7211 21.7867 42.68%
2005 14.3133 14.2748 16.1417 12.2518 15.2699 4.04%
2004 18.7378 20.6924 21.6044 11.7119 14.6767 -27.77%
2003 22.2016 23.5435 25.9055 17.7003 20.3186 -11.20%
2002 21.5265 23.5388 25.4990 15.5687 22.8806 -1.21%
2001 27.7506 35.9255 35.9255 22.5186 23.1607 -35.96%
2000 28.2445 25.6786 36.6015 20.5781 36.1669 41.76%
1999 27.5742 27.9972 32.4075 22.9544 25.5125 -7.48%
1998 23.8872 19.8153 29.6682 18.9408 27.5766 41.30%
1997 17.2173 14.4325 19.7578 14.4325 19.5162 35.65%
1996 12.1649 11.3653 15.1476 10.1329 14.3873 23.94%
1995 8.6446 6.5950 11.8297 6.2933 11.6086 76.60%
1994 5.6344 5.8691 6.7890 4.7662 6.5735 14.85%
1993 5.7471 7.0892 7.0892 4.7058 5.7235 -18.33%
1992 7.7599 8.7883 8.9204 6.6085 7.0084 -20.31%
1991 6.2738 4.6366 8.7949 4.2610 8.7949 88.89%
1990 4.0395 3.9712 4.6560 3.4124 4.6560 18.95%
1989 3.5158 2.8224 4.0176 2.8224 3.9144 37.49%
1988 2.6640 2.6375 2.9137 2.3347 2.8471 11.95%
1987 2.6746 1.9903 3.4736 1.9903 2.5433 29.98%
1986 1.4953 1.0676 2.0456 1.0473 1.9567 84.61%
1985 0.8371 0.6995 1.0599 0.6789 1.0599 50.11%
1984 0.6530 0.6557 0.7094 0.5884 0.7061 7.69%
1983 0.6494 0.5906 0.7505 0.5765 0.6557 10.20%
1982 0.5301 0.5793 0.6170 0.4435 0.5950 3.62%
1981 0.5792 0.5653 0.6826 0.5141 0.5742 3.07%
1980 0.4701 0.4498 0.5571 0.3770 0.5571 21.29%
1979 0.4225 0.4190 0.4681 0.3923 0.4593 10.04%
1978 0.3500 0.3212 0.4267 0.2906 0.4174 25.57%
1977 0.3313 0.3902 0.3902 0.2953 0.3324 -16.23%
1976 0.4118 0.3971 0.4654 0.3669 0.3968 0.48%
1975 0.4206 0.3766 0.4831 0.3290 0.3949 6.24%
1974 0.3997 0.4435 0.4767 0.2744 0.3717 -16.58%
1973 0.4888 0.4923 0.5484 0.4273 0.4456 -8.09%
1972 0.4133 0.3368 0.4861 0.3368 0.4848 45.41%
1971 0.2821 0.2503 0.3516 0.2503 0.3334 27.84%
1970 0.2417 0.2877 0.2903 0.1928 0.2608 -10.78%
1969 0.2442 0.2337 0.2948 0.2140 0.2923 25.56%
1968 0.2203 0.2095 0.2457 0.1907 0.2328 6.69%
1967 0.2146 0.1946 0.2428 0.1927 0.2182 9.92%
1966 0.1910 0.1856 0.2089 0.1684 0.1985 8.89%
1965 0.1515 0.1254 0.1927 0.1254 0.1823 41.98%
1964 0.1060 0.0952 0.1284 0.0892 0.1284 36.02%
1963 0.0805 0.0671 0.0945 0.0671 0.0944 41.11%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.100B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $744.001B 57.05
Johnson & Johnson (JNJ) United States $362.667B 15.00
AbbVie (ABBV) United States $327.650B 18.06
Roche Holding AG (RHHBY) Switzerland $252.694B 0.00
Novartis AG (NVS) Switzerland $244.956B 13.99
Pfizer (PFE) United States $135.767B 7.44
Sanofi (SNY) France $116.786B 11.50
Bayer (BAYRY) Germany $30.534B 6.22
Innoviva (INVA) United States $1.347B 14.12
Novo Nordisk (NVO) Denmark $0.000B 21.90